Rosenberg spoke with Outsourcing-pharma at DIA Euro Meeting in Monaco and explained that although adaptive clinical trial design is a well established practice, CROs and drugmakers have only "scraped the surface" in the use of an adaptive approach to trial operations.
He highlighted enrollment as one operational area that could be improved explaining that Health Decisions' research indicates that 76 per cent of adaptive trials meet enrollment timelines compared with just 15 per cent of traditional studies.
The other advantage of an adaptive approach to trial operations is that, unlike adaptive changes at the design level, they do not require regulatory approval and thus give CROs and sponsors direct control over some of the most costly and time consuming aspects of a clinical study.